Loading...
LAVI logo

Lavipharm S.A.ATSE:LAVI Stock Report

Market Cap €256.2m
Share Price
n/a
1Y84.0%
7D-1.6%
1D-1.7%
Portfolio Value
​
View

Lavipharm S.A.

ATSE:LAVI Stock Report

Market Cap: €256.2m

Lavipharm (LAVI) Stock Overview

Engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. More details

LAVI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends0/6

Risk Analysis

Profit margins (8%) are lower than last year (16.3%)

Has a high level of debt


LAVI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW490,690 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
490,690 investors already sharing narratives
View all narratives

Lavipharm S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lavipharm
Historical stock prices
Current Share Price€1.50
52 Week High€1.74
52 Week Low€0.76
Beta1
1 Month Change-2.98%
3 Month Change5.63%
1 Year Change84.05%
3 Year Change119.30%
5 Year Change5.93%
Change since IPO-81.08%

Recent News & Updates

Analysis Article • May 01

Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) Shareholders

Lavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...

Recent updates

Analysis Article • May 01

Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) Shareholders

Lavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...
Analysis Article • Jan 28

Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance Completely

Despite an already strong run, Lavipharm S.A. ( ATH:LAVI ) shares have been powering on, with a gain of 27% in the last...
Analysis Article • Dec 18

Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Apr 10

We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) Profit

The latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...
Analysis Article • Sep 26

Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They Appear

Despite posting strong earnings, Lavipharm S.A.'s ( ATH:LAVI ) stock didn't move much over the last week. We looked...
Analysis Article • Aug 06

Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E Ratio

With a price-to-earnings (or "P/E") ratio of 61.9x Lavipharm S.A. ( ATH:LAVI ) may be sending very bearish signals at...
Analysis Article • Nov 01

Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt Burden

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Feb 11

We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory Profitability

Broadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...

Shareholder Returns

LAVIGR PharmaceuticalsGR Market
7D-1.6%-3.9%-0.8%
1Y84.0%14.8%22.8%

Return vs Industry: LAVI exceeded the Greek Pharmaceuticals industry which returned 13.1% over the past year.

Return vs Market: LAVI exceeded the Greek Market which returned 21.5% over the past year.

Price Volatility

Is LAVI's price volatile compared to industry and market?
LAVI volatility
LAVI Average Weekly Movement4.5%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.0%
10% most volatile stocks in GR Market6.4%
10% least volatile stocks in GR Market2.5%

Stable Share Price: LAVI has not had significant price volatility in the past 3 months compared to the Greek market.

Volatility Over Time: LAVI's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1911285Telemaque Lavidaslavipharm.com

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products.

Lavipharm S.A. Fundamentals Summary

How do Lavipharm's earnings and revenue compare to its market cap?
LAVI fundamental statistics
Market cap€256.17m
Earnings (TTM)€5.18m
Revenue (TTM)€64.53m
49.5x
P/E Ratio
4.0x
P/S Ratio

Is LAVI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LAVI income statement (TTM)
Revenue€64.53m
Cost of Revenue€33.68m
Gross Profit€30.86m
Other Expenses€25.68m
Earnings€5.18m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Sep 17, 2026

Earnings per share (EPS)0.03
Gross Margin47.81%
Net Profit Margin8.02%
Debt/Equity Ratio58.1%

How did LAVI perform over the long term?

See historical performance and comparison

Dividends

1.3%
Current Dividend Yield
172%
Payout Ratio

Does LAVI pay a reliable dividends?

See LAVI dividend history and benchmarks
When do you need to buy LAVI by to receive an upcoming dividend?
Lavipharm dividend dates
Ex Dividend DateJul 20 2026
Dividend Pay DateJul 24 2026
Days until Ex dividend8 days
Days until Dividend pay date12 days

Does LAVI pay a reliable dividends?

See LAVI dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 15:40
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lavipharm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.